We don't know whether the most recent response to this request contains information or not – if you are Phil Early please sign in and let everyone know.

Questions in relation to Breast Cancer Treatment

Phil Early made this Freedom of Information request to Lancashire Teaching Hospitals NHS Foundation Trust as part of a batch sent to 217 authorities

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

We're waiting for Phil Early to read a recent response and update the status.

Dear Lancashire Teaching Hospitals NHS Foundation Trust,

I would like to please request the following information with regards to Breast Cancer Treatment.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

• Abemaciclib (Verzenios) + aromatase inhibitor *
• Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
• Alpelisib (Piqray) + Fulvestrant (Faslodex)
• Atezolizumab (Tecentriq)**
• Bevacizumab (Avastin)
• Eribulin (Halaven)
• Everolimus (Afinitor) + Exemestane
• Fulvestrant (Faslodex) as a single agent
• Gemcitabine + paclitaxel
• Herceptin (Trastuzumab) + paclitaxel
• Herceptin (Trastuzumab) as a single agent
• Lapatinib (Tyverb)
• Neratinib (Nerlynx)
• Olaparib (Lynparza)
• Palbociclib (Ibrance) + aromatase inhibitor*
• Palbociclib (Ibrance) + Fulvestrant (Faslodex)
• Pertuzumab (Perjeta) + trastuzumab + docetaxel
• Ribociclib (Kisqali) + aromatase inhibitor*
• Ribociclib (Kisqali) + Fulvestrant (Faslodex)
• Talazoparib (Talzenna)
• Trastuzumab emtansine (Kadcyla)
• Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

Thank you for answering these questions.

Yours faithfully,

Phil Early

Freedom of Information (LTHTR), Lancashire Teaching Hospitals NHS Foundation Trust

Dear Phil Early,

In order to proceed clarification is required on the below point:

What organisation is this request being submitted by/on behalf of?

Regards,

Freedom of Information Officer

Technology Services | Lancashire Teaching Hospitals NHS Foundation Trust | Royal Preston Hospital | Sharoe Green Lane | Preston | Lancashire | PR2 9HT
Email: [Lancashire Teaching Hospitals NHS Foundation Trust request email] | Website: www.lancsteachinghospitals.nhs.uk

show quoted sections

Dear Freedom of Information (LTHTR),
The FOI request has been made by NeoSypher using the portal "whatdotheyknow"
This request is one of many that form a larger query, which we split into five smaller queries. Our apologies if this has caused any confusion.

Yours sincerely,

Phil Early
www.neosypher.com

Freedom of Information (LTHTR), Lancashire Teaching Hospitals NHS Foundation Trust

Dear NeoSypher,

The trust declines to respond under section 12 due to the collective volume of information being requested at one time by your organisation.

FOI Request 8353

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the following treatments:

. Revolade (eltrombopag)
. Nplate (romiplostim)
. Doptelet (avatrombopag)
. Tavlesse (fostamatinib)

Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

rituximab
mycophenolate mofetil
surgery (splenectomy)

Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

FOI Request 8355

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to?

Q2.

A) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4).

b) How many of these patients were above age 65?

Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib?

Q4.

A) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

. Hydroxyurea
. Fedratinib
. Received No Treatment

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

FOI Request 8356

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

. Bevacizumab (Avastin)
. Dacarbazine (DTIC)
. Trametinib (Mekinist)
. Dabrafenib (Tafinlar)
. Ipilimumab (Yervoy)
. Vemurafenib (Zelboraf)
. Nivolumab (Opdivo)
. Nivolumab + Ipilimumab (Opdivo + Yervoy)
. Pembrolizumab (Keytruda)
. Vemurafenib + cobimetinib (Zelboraf + Cotellic)
. Dabrafenib + Trametinib (Tafinlar + Mekinist)
. Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
. Other active systemic anti-cancer therapy [please state]
. Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

. Ipilimumab
. Ipilimumab AND Nivolumab
. Nivolumab
. Pembrolizumab
. Dabrafenib AND Trametinib
. Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
. Other active systemic anti-cancer therapy
. Palliative care only

FOI Request 8357

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:

Q1 Q2
. Abemaciclib (Verzenios) + aromatase inhibitor *
. Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
. Alpelisib (Piqray) + Fulvestrant (Faslodex)
. Atezolizumab (Tecentriq)**
. Bevacizumab (Avastin)
. Eribulin (Halaven)
. Everolimus (Afinitor) + Exemestane
. Fulvestrant (Faslodex) as a single agent
. Gemcitabine + paclitaxel
. Herceptin (Trastuzumab) + paclitaxel
. Herceptin (Trastuzumab) as a single agent
. Lapatinib (Tyverb)
. Neratinib (Nerlynx)
. Olaparib (Lynparza)
. Palbociclib (Ibrance) + aromatase inhibitor*
. Palbociclib (Ibrance) + Fulvestrant (Faslodex)
. Pertuzumab (Perjeta) + trastuzumab + docetaxel
. Ribociclib (Kisqali) + aromatase inhibitor*
. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
. Talazoparib (Talzenna)
. Trastuzumab emtansine (Kadcyla)
. Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

FOI Request 8358

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

. Afatinib
. Alectinib
. Atezolizumab monotherapy
. Atezolizumab in combination
. Bevacizumab
. Brigatinib
. Capmatenib
. Ceritinib
. Crizotinib
. Dacomitinib
. Dabrafenib with Trametinib
. Docetaxel monotherapy
. Durvalumab
. Erlotinib
. Gefitinib
. Gemcitabine
. Nintedanib with Docetaxel
. Nivolumab
. Osimertinib
. Paclitaxel
. Pembrolizumab monotherapy
. Pembrolizumab in combination
. Pemetrexed with Carboplatin/Cisplatin
. Tepotinib
. Vinorelbine with Cisplatin/Carboplatin
. Any other SACT
. Palliative care only

Trust response: Response exempt under section 12

Regards,

Freedom of Information Officer
 
Technology Services | Lancashire Teaching Hospitals NHS Foundation Trust | Royal Preston Hospital | Sharoe Green Lane | Preston | Lancashire | PR2 9HT
Email: [Lancashire Teaching Hospitals NHS Foundation Trust request email] | Website: www.lancsteachinghospitals.nhs.uk

show quoted sections

We don't know whether the most recent response to this request contains information or not – if you are Phil Early please sign in and let everyone know.